Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

China propaganda kicks into overdrive as 'helmsman' Xi re-anointed president

Mar 18, 2018

By Ben BlanchardBEIJING (Reuters) - With pictures of ecstatic citizens standing in applause, happily tearful legislators and even a social media game, China's propaganda drive has kicked into high gear following Xi Jinping's unanimous reappointment as president.Xi's face dominated the front pages of major Sunday newspapers, many carrying the same editorial from the ruling Communist Party's official People's Daily using language once more associated with Mao Zedong to say he was a "leader loved and respected by the people" and "helmsman of the country"."The voyage of a great country cannot do without a helmsman," the paper wrote.The military's official People's...

China plans tougher goals, beefed-up inspections in war on smog

Mar 18, 2018

BEIJING (Reuters) - China will set more stringent targets for improving the nation's air quality under a new three-year plan, as Beijing prepares to beef up a nationwide crackdown on polluters in its years-long campaign to clear its notoriously toxic skies.The new targets for concentrations of small, breathable particles known as PM2.5 will be lower than those in the country's current five-year plan that was due to end in 2020, environment minister Li Ganjie said at a briefing on the sidelines of the country's annual Parliament on Saturday.In January, the Ministry of Environmental Protection (MEP) said it was drawing up...

JD.com's finance unit aims to raise $1.9 billion, valuation set to double: sources

Mar 18, 2018

By Julie ZhuHONG KONG (Reuters) - JD.com Inc's finance arm is looking to raise about 12 billion yuan ($1.9 billion) in fresh equity that could see its value double from last year to more than $20 billion, three people with knowledge of the matter said.The unit of China's second-largest e-commerce firm is seeking to deepen its push into areas such as securities, banking and insurance - businesses that have seen the entry of several new technology-focused players.The move adds to a flurry of fundraising by Chinese tech firms keen to respond to burgeoning demand for digital services, especially in the...

Chamber of Commerce warns Trump against China tariffs

Mar 18, 2018

WASHINGTON (Reuters) - The head of the most influential U.S. business lobbying group warned the Trump administration that unilateral tariffs on Chinese goods could lead to a destructive trade war that will hurt American consumers and U.S. economic growth.U.S. Chamber of Commerce President Thomas Donohue said in a statement on Thursday that such tariffs, associated with a probe of China's intellectual property practices, would be "damaging taxes on American consumers."His comments came after White House trade adviser Peter Navarro said that Trump would in coming weeks get options to address China's "theft and forced transfer" of American intellectual property as...

Leshi shares plunge after 'white knight' chairman resigns

Mar 18, 2018

By Sijia JiangHONG KONG (Reuters) - Shares in Leshi Internet Information & Technology Corp Beijing slumped 10 percent on Friday after its chairman resigned, fanning fears he would no longer play a white knight role for the embattled firm.Sun Hongbin took on the job only eight months ago after a $2.2 billion investment by his property firm Sunac China Holdings, and had been seen as the main backer for the crumbling LeEco conglomerate, of which Leshi has been the main listed vehicle.But financial woes at LeEco, which once aspired to be both China's Netflix and Tesla, have only deepened with...

Sign up now!